Antipsychotic drug binding in the substantia nigra: An examination of high metoclopramide binding in the brains of normal, Alzheimer's disease, Huntington's disease, and Multiple Sclerosis patients, and its relation to tardive dyskinesia
Identifieur interne : 001889 ( Main/Exploration ); précédent : 001888; suivant : 001890Antipsychotic drug binding in the substantia nigra: An examination of high metoclopramide binding in the brains of normal, Alzheimer's disease, Huntington's disease, and Multiple Sclerosis patients, and its relation to tardive dyskinesia
Auteurs : Sheng Chen [Canada] ; Philip Seeman [Canada] ; Fang Liu [Canada]Source :
- Synapse [ 0887-4476 ] ; 2011-02.
English descriptors
- KwdEn :
Abstract
This project was done in order to determine why the annual incidence of metoclopramide‐associated tardive dyskinesia is much higher than that for the commonly used antipsychotics. To test the hypothesis that metoclopramide tardive dyskinesia may be associated with high concentrations of metoclopramide in the substantia nigra under clinical conditions, the nonspecific binding of tritiated antipsychotics to the dissected melaninized regions of postmortem human substantia nigra was measured. The nonspecific binding at 1 nM [3H]ligand was 7.3, 4.2, 2.6, 0.91 and 0.66 fmoles/mg for [3H]haloperidol, [3H]clozapine, [3H]raclopride, [3H]metoclopramide, and [3H]olanzapine, respectively. After adjusting these values for the known free concentrations of these drugs in plasma or spinal fluid, the amounts that would be bound under clinical conditions would be 231, 113, 15, 11, and 3.4 fmoles/mg for metoclopramide, clozapine, raclopride, haloperidol, and olanzapine, respectively. Using rat striatum as baseline to define antipsychotic binding to nonnigral tissue, the excess amount of binding to the Alzheimer nigral tissue under clinical conditions would be 209, 19, 0, 3.4 and 0.8 fmole/mg for metoclopramide, clozapine, raclopride, haloperidol, and olanzapine, respectively, with a similar pattern for nigral tissues from Huntington and Multiple Sclerosis patients. The high accumulation of metoclopramide is sufficiently high to cause nigral nerve cell membrane damage by metoclopramide's detergent‐like action, possibly explaining metoclopramide's toxic ability to elicit early tardive dyskinesia. In addition, the nonspecific binding of metoclopramide was much higher in Alzheimer‐diseased substantia nigra, consistent with the fact that older individuals are relatively more vulnerable to metoclopramide tardive dyskinesia. Synapse, 2011. © 2010 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/syn.20825
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001B73
- to stream Istex, to step Curation: 001B73
- to stream Istex, to step Checkpoint: 000474
- to stream Main, to step Merge: 001967
- to stream Main, to step Curation: 001889
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antipsychotic drug binding in the substantia nigra: An examination of high metoclopramide binding in the brains of normal, Alzheimer's disease, Huntington's disease, and Multiple Sclerosis patients, and its relation to tardive dyskinesia</title><author><name sortKey="Chen, Sheng" sort="Chen, Sheng" uniqKey="Chen S" first="Sheng" last="Chen">Sheng Chen</name></author><author><name sortKey="Seeman, Philip" sort="Seeman, Philip" uniqKey="Seeman P" first="Philip" last="Seeman">Philip Seeman</name></author><author><name sortKey="Liu, Fang" sort="Liu, Fang" uniqKey="Liu F" first="Fang" last="Liu">Fang Liu</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:185DCDE32B673A5B76896DA3347CA2D290D97636</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/syn.20825</idno><idno type="url">https://api-v5.istex.fr/document/185DCDE32B673A5B76896DA3347CA2D290D97636/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001B73</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001B73</idno><idno type="wicri:Area/Istex/Curation">001B73</idno><idno type="wicri:Area/Istex/Checkpoint">000474</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000474</idno><idno type="wicri:doubleKey">0887-4476:2011:Chen S:antipsychotic:drug:binding</idno><idno type="wicri:Area/Main/Merge">001967</idno><idno type="wicri:Area/Main/Curation">001889</idno><idno type="wicri:Area/Main/Exploration">001889</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Antipsychotic drug binding in the substantia nigra: An examination of high metoclopramide binding in the brains of normal, Alzheimer's disease, Huntington's disease, and Multiple Sclerosis patients, and its relation to tardive dyskinesia</title><author><name sortKey="Chen, Sheng" sort="Chen, Sheng" uniqKey="Chen S" first="Sheng" last="Chen">Sheng Chen</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Seeman, Philip" sort="Seeman, Philip" uniqKey="Seeman P" first="Philip" last="Seeman">Philip Seeman</name><affiliation wicri:level="4"><country>Canada</country><wicri:regionArea>Department of Pharmacology, University of Toronto, 260 Heath St., West, Suite 605, Toronto</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="4"><country>Canada</country><wicri:regionArea>Department of Pharmacology, University of Toronto, 260 Heath St., West, Suite 605, Toronto</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Liu, Fang" sort="Liu, Fang" uniqKey="Liu F" first="Fang" last="Liu">Fang Liu</name><affiliation wicri:level="4"><country>Canada</country><wicri:regionArea>Department of Pharmacology, University of Toronto, 260 Heath St., West, Suite 605, Toronto</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Synapse</title><title level="j" type="abbrev">Synapse</title><idno type="ISSN">0887-4476</idno><idno type="eISSN">1098-2396</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-02">2011-02</date><biblScope unit="volume">65</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="119">119</biblScope><biblScope unit="page" to="124">124</biblScope></imprint><idno type="ISSN">0887-4476</idno></series><idno type="istex">185DCDE32B673A5B76896DA3347CA2D290D97636</idno><idno type="DOI">10.1002/syn.20825</idno><idno type="ArticleID">SYN20825</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0887-4476</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>antipsychotics</term><term>clozapine</term><term>haloperidol</term><term>metoclopramide</term><term>olanzapine</term><term>schizophrenia</term><term>substantia nigra</term><term>tardive dyskinesia</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This project was done in order to determine why the annual incidence of metoclopramide‐associated tardive dyskinesia is much higher than that for the commonly used antipsychotics. To test the hypothesis that metoclopramide tardive dyskinesia may be associated with high concentrations of metoclopramide in the substantia nigra under clinical conditions, the nonspecific binding of tritiated antipsychotics to the dissected melaninized regions of postmortem human substantia nigra was measured. The nonspecific binding at 1 nM [3H]ligand was 7.3, 4.2, 2.6, 0.91 and 0.66 fmoles/mg for [3H]haloperidol, [3H]clozapine, [3H]raclopride, [3H]metoclopramide, and [3H]olanzapine, respectively. After adjusting these values for the known free concentrations of these drugs in plasma or spinal fluid, the amounts that would be bound under clinical conditions would be 231, 113, 15, 11, and 3.4 fmoles/mg for metoclopramide, clozapine, raclopride, haloperidol, and olanzapine, respectively. Using rat striatum as baseline to define antipsychotic binding to nonnigral tissue, the excess amount of binding to the Alzheimer nigral tissue under clinical conditions would be 209, 19, 0, 3.4 and 0.8 fmole/mg for metoclopramide, clozapine, raclopride, haloperidol, and olanzapine, respectively, with a similar pattern for nigral tissues from Huntington and Multiple Sclerosis patients. The high accumulation of metoclopramide is sufficiently high to cause nigral nerve cell membrane damage by metoclopramide's detergent‐like action, possibly explaining metoclopramide's toxic ability to elicit early tardive dyskinesia. In addition, the nonspecific binding of metoclopramide was much higher in Alzheimer‐diseased substantia nigra, consistent with the fact that older individuals are relatively more vulnerable to metoclopramide tardive dyskinesia. Synapse, 2011. © 2010 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Canada"><noRegion><name sortKey="Chen, Sheng" sort="Chen, Sheng" uniqKey="Chen S" first="Sheng" last="Chen">Sheng Chen</name></noRegion><name sortKey="Liu, Fang" sort="Liu, Fang" uniqKey="Liu F" first="Fang" last="Liu">Fang Liu</name><name sortKey="Seeman, Philip" sort="Seeman, Philip" uniqKey="Seeman P" first="Philip" last="Seeman">Philip Seeman</name><name sortKey="Seeman, Philip" sort="Seeman, Philip" uniqKey="Seeman P" first="Philip" last="Seeman">Philip Seeman</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001889 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001889 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:185DCDE32B673A5B76896DA3347CA2D290D97636
|texte= Antipsychotic drug binding in the substantia nigra: An examination of high metoclopramide binding in the brains of normal, Alzheimer's disease, Huntington's disease, and Multiple Sclerosis patients, and its relation to tardive dyskinesia
}}
| This area was generated with Dilib version V0.6.29. |  |